Alkermes Stock Price, News & Analysis (NASDAQ:ALKS) $24.29 +0.15 (+0.62%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$24.00▼$24.4350-Day Range$23.37▼$29.1052-Week Range$22.01▼$33.71Volume4.35 million shsAverage Volume1.77 million shsMarket Capitalization$4.05 billionP/E Ratio19.59Dividend YieldN/APrice Target$32.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside32.9% Upside$32.29 Price TargetShort InterestHealthy4.77% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth59.26%From $1.08 to $1.72 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.01 out of 5 starsMedical Sector20th out of 955 stocksPharmaceutical Preparations Industry6th out of 447 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.29, Alkermes has a forecasted upside of 32.9% from its current price of $24.29.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.77% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Alkermes has recently decreased by 0.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 2.1 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alkermes this week, compared to 4 articles on an average week.Search Interest10 people have searched for ALKS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to grow by 59.26% in the coming year, from $1.08 to $1.72 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 19.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 106.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 19.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesDecember 2, 2023 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by BrokeragesNovember 26, 2023 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Lifted to "Strong-Buy" at StockNews.comDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 24, 2023 | finance.yahoo.comWhy Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report?November 20, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF), Alkermes (ALKS) and Olink Holding (OLK)November 17, 2023 | bizjournals.comWhy Alkermes spun out an oncology company, whose shares have plummetedNovember 16, 2023 | finanznachrichten.deAlkermes plc: Alkermes Completes Separation of Oncology Business into Mural Oncology plcNovember 15, 2023 | finanznachrichten.deAlkermes Completes Separation Of Oncology Business; Updates 2023 GuidanceDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | finance.yahoo.comAlkermes Completes Separation of Oncology BusinessNovember 14, 2023 | finance.yahoo.comAlkermes (ALKS) Proprietary Drugs Aid Growth Amid CompetitionNovember 13, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF), Alkermes (ALKS) and Dexcom (DXCM)November 10, 2023 | seekingalpha.comAlkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-RateNovember 8, 2023 | seekingalpha.comAlkermes' OX2R Agonist For Narcolepsy Peaks Interest Amidst Strong Q3 EarningsNovember 7, 2023 | stocknews.comBiogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?November 7, 2023 | finance.yahoo.comAlkermes to Participate in the Jefferies London Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comAlkermes Announces Effectiveness of Mural Oncology Form 10 Registration StatementOctober 30, 2023 | stocknews.comAmgen (AMGN) Earnings Watch: Buy or Sell?October 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Blueprint Medicines (BPMC)October 27, 2023 | msn.comPiper Sandler Maintains Alkermes (ALKS) Overweight RecommendationOctober 27, 2023 | msn.comMizuho Maintains Alkermes (ALKS) Buy RecommendationOctober 26, 2023 | finance.yahoo.comAlkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call TranscriptOctober 26, 2023 | finance.yahoo.comAlkermes (ALKS) Down Despite Q3 Earnings & Revenue BeatOctober 25, 2023 | markets.businessinsider.comHold Rating on Alkermes’ Stock: Leerink Partners Cites Early Efficacy Data and Tolerability Concerns for ALKS2680 Narcolepsy TreatmentOctober 25, 2023 | finanznachrichten.deAlkermes Turns To Profit In Q3, Beats Estimates; Backs Full-year OutlookOctober 25, 2023 | finance.yahoo.comAlkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to SayOctober 25, 2023 | msn.comAlkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 OutlookSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/25/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,280Year Founded1987Price Target and Rating Average Stock Price Target$32.29 High Stock Price Target$35.00 Low Stock Price Target$28.00 Potential Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$1.24 Trailing P/E Ratio19.59 Forward P/E Ratio22.49 P/E GrowthN/ANet Income$-158,270,000.00 Net Margins13.50% Pretax Margin13.68% Return on Equity11.41% Return on Assets6.40% Debt Debt-to-Equity Ratio0.21 Current Ratio2.91 Quick Ratio2.53 Sales & Book Value Annual Sales$1.11 billion Price / Sales3.65 Cash Flow$0.25 per share Price / Cash Flow95.65 Book Value$8.12 per share Price / Book2.99Miscellaneous Outstanding Shares166,880,000Free Float158,937,000Market Cap$4.05 billion OptionableOptionable Beta0.64 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 61)Chairman & CEO Comp: $2.3MMr. Iain Michael Brown (Age 54)Senior VP & CFO Comp: $867.75kMr. Blair C. Jackson (Age 50)Executive VP & COO Comp: $1.05MMr. David Joseph Gaffin (Age 51)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.08MDr. Craig C. Hopkinson M.D. (Age 55)Executive VP of Research & Development and Chief Medical Officer Comp: $1.12MDr. Floyd E. Bloom M.D. (Age 86)Founder Comp: $57.73kMr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Michael J. Landine (Age 69)Senior VP of Corporate Development & Chief Risk Officer Comp: $750.46kMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXSotera HealthNASDAQ:SHCEnvistaNYSE:NVSTSurgery PartnersNASDAQ:SGRYMerit Medical SystemsNASDAQ:MMSIView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 4,055,926 shares on 12/1/2023Ownership: 7.039%American Century Companies Inc.Bought 229,181 shares on 11/30/2023Ownership: 0.526%Neo Ivy Capital ManagementBought 20,132 shares on 11/30/2023Ownership: 0.012%Deutsche Bank AGBought 13,945 shares on 11/24/2023Ownership: 0.130%Graham Capital Management L.P.Bought 38,581 shares on 11/22/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 7 analysts have issued 12 month price targets for Alkermes' shares. Their ALKS share price targets range from $28.00 to $35.00. On average, they predict the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2023? Alkermes' stock was trading at $26.13 on January 1st, 2023. Since then, ALKS shares have decreased by 7.0% and is now trading at $24.29. View the best growth stocks for 2023 here. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) announced its quarterly earnings results on Wednesday, October, 25th. The company reported $0.50 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.19. The company earned $380.94 million during the quarter, compared to analysts' expectations of $366.18 million. Alkermes had a trailing twelve-month return on equity of 11.41% and a net margin of 13.50%. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB). What guidance has Alkermes issued on next quarter's earnings? Alkermes updated its FY23 earnings guidance on Wednesday, November, 15th. The company provided earnings per share (EPS) guidance of $1.57-$1.75 for the period, compared to the consensus EPS estimate of $1.58. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.04%), Hardman Johnston Global Advisors LLC (3.37%), Primecap Management Co. CA (2.33%), Bank of New York Mellon Corp (1.66%), Charles Schwab Investment Management Inc. (1.30%) and Morgan Stanley (1.21%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.